Forecasting The Future: 5 Analyst Projections For PROCEPT BioRobotics
Benzinga Insights 8 months ago
Analyst Ratings
In the preceding three months, 5 analysts have released ratings for PROCEPT BioRobotics (NASDAQ:PRCT), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 1 | 1 | 1 | 0 |
| Last 30D | 0 | 0 | 0 | 1 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 2 | 1 | 1 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $43.6, a high estimate of $62.00, and a low estimate of $20.00. This current average represents a 12.36% decrease from the previous average price target of $49.75.
Investigating Analyst Ratings: An Elaborate Study
An in-depth analysis of recent analyst actions unveils how financial experts perceive PROCEPT BioRobotics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Craig Bijou | B of A Securities | Lowers | Underperform | $20.00 | $38.00 |
| Richard Newitter | Truist Securities | Lowers | Buy | $47.00 | $50.00 |
| Danielle Antalffy | UBS | Announces | Buy | $62.00 | - |
| Craig Bijou | B of A Securities | Lowers | Neutral | $38.00 | $55.00 |
| Patrick Wood | Morgan Stanley | Lowers | Overweight | $51.00 | $56.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to PROCEPT BioRobotics. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of PROCEPT BioRobotics compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of PROCEPT BioRobotics's stock. This examination reveals shifts in analysts' expectations over time.
Capture valuable insights into PROCEPT BioRobotics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on PROCEPT BioRobotics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Get to Know PROCEPT BioRobotics Better
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
PROCEPT BioRobotics's Economic Impact: An Analysis
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: PROCEPT BioRobotics's remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of 42.76%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: PROCEPT BioRobotics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -25.7%, the company may face hurdles in effective cost management.
Return on Equity (ROE): PROCEPT BioRobotics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -5.59%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -4.18%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: PROCEPT BioRobotics's debt-to-equity ratio is below the industry average at 0.21, reflecting a lower dependency on debt financing and a more conservative financial approach.
The Significance of Analyst Ratings Explained
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.